Contribution of abnormal BMI to adverse health-related quality of life outcomes after a 52-week therapy in patients with SLE

OBJECTIVES: To investigate whether abnormal BMI is associated with adverse health-related quality of life (HRQoL) outcome, including severe fatigue, after 52 weeks of standard therapy plus belimumab or placebo in patients with SLE. METHODS: We analysed data from the BLISS-52 (NCT00424476) and BLISS-...

Descripción completa

Detalles Bibliográficos
Autores principales: Borg, Alexander, Gomez, Alvaro, Cederlund, Arvid, Cobar, Flordelyn, Qiu, Victor, Lindblom, Julius, Emamikia, Sharzad, Enman, Yvonne, Pettersson, Susanne, Parodis, Ioannis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410008/
https://www.ncbi.nlm.nih.gov/pubmed/33404659
http://dx.doi.org/10.1093/rheumatology/keaa909

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410008/
https://www.ncbi.nlm.nih.gov/pubmed/33404659
http://dx.doi.org/10.1093/rheumatology/keaa909

Ejemplares similares